Steglatro (generic name: ertugliflozin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. Ertugliflozin acts as a blocker for the SGLT2 protein in the kidney tubules, whose primary function is to reabsorb the glucose from the filtered liquid back into the body. By doing this, the drug ensures that glucose is expelled through urine instead and not taken back into the bloodstream. As well as this effect on glucose, Steglatro also affects the handling of salt in the kidneys. The effects of this include reducing the heart’s workload and decreasing the internal pressure inside the kidney’s filtering units. The benefits include:

• An improvement in glycemic control for adults with type 2 diabetes
• A reduction in the risk of sustained kidney damage from high salt excretion
• A reduction in the risks of heart failure for adult patients suffering from kidney failure

Dosage

The prescribing doctor sets the dosage based on each patient’s underlying condition. It is essential to follow the prescribing doctor’s instructions. Read the Patient Information leaflet that comes with the package.